Business Wire
-
Parallel Bio Launches Clinical Trial In A Dish To Speed Drug Discovery
5/16/2024
Parallel Bio, a biotech company using the immune system to cure disease, today announced the release of its Clinical Trial in a Dish for studying the efficacy and safety of new immunotherapies using human models at the earliest stages of drug discovery.
-
Ajax Therapeutics Announces FDA Clearance Of IND Application For AJ1-11095, A First-In-Class Type II JAK2 Inhibitor, For The Treatment Of Myelofibrosis
5/13/2024
Ajax Therapeutics, Inc., a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), today announced that it has received clearance for its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1clinical study of AJ1‑11095, a first-in-class Type II JAK2 inhibitor, for the treatment of patients with myelofibrosis.
-
Avicenna Introduces Machine Learning-Enhanced Medicinal Chemistry Platform To Accelerate The Last Mile Of Small Molecule Drug Discovery
5/8/2024
Avicenna Biosciences today introduced an extension to its machine learning (ML) technology platform to enhance medicinal chemistry and expedite clinical-stage drug discovery.
-
Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration To Optimize Development Of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor Of Cancer Metabolism
5/6/2024
Lantern Pharma Inc. a leading artificial intelligence (AI) oncology drug discovery and development company, today announced a strategic AI-driven collaboration with French biotechnology company, Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase (PDI)(1) inhibitor drug candidate XCE853 in novel and targeted cancer indications.
-
U.S. Food And Drug Administration Accepts Bristol Myers Squibb’s Application For Subcutaneous Nivolumab (nivolumab And hyaluronidase)
5/6/2024
Bristol Myers Squibb today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for the subcutaneous formulation of Opdivo (nivolumab) co-formulated with Halozyme’s proprietary recombinant human hyaluronidase (rHuPH20) (herein referred to as “subcutaneous nivolumab”) across all previously approved adult, solid tumor Opdivo indications as monotherapy, monotherapy maintenance following completion of Opdivo plus Yervoy (ipilimumab) combination therapy, or in combination with chemotherapy or cabozantinib.
-
VantAI Collaborates With Google Cloud To Harness NVIDIA GPUs For Building Protein Interaction Foundation Models
5/1/2024
VantAI, a pioneer in generative AI-enabled drug discovery, is working with Google Cloud to power large scale distributed training and further improve internal operations.
-
Every Cure Deploys BioPhy’s Artificial Intelligence Platform To Accelerate Its Mission Of Repurposing Drugs For Untreated Diseases
4/30/2024
BioPhy, an innovative AI drug development company, today announced a partnership with Every Cure, a nonprofit initiative on a mission to unlock the full potential of existing medicines to treat every disease and every patient they possibly can.
-
Scenic Biotech Enters Into Research Collaboration With Bristol Myers Squibb
4/30/2024
Scenic Biotech, a pioneer in the field of modifier therapies for severe genetic disorders, today announced that it has entered into a research collaboration with Bristol Myers Squibb to accelerate the development of Bristol Myers Squibb’s drug targets by identifying target biology for indication selection and expansion.
-
Xaira Therapeutics Launches To Deliver Transformative Medicines By Advancing And Harnessing AI For Drug Discovery And Development
4/23/2024
Xaira Therapeutics launched today on a mission to help re-engineer the way we discover and develop medicines through the end-to-end application of emerging AI technologies.
-
Shorla Oncology Announces FDA Filing Acceptance Of New Drug Application To Treat Certain Forms Of Leukemia And Other Cancers
4/8/2024
Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) for SH-201, the first palatable oral liquid of the related chemotherapeutic agent to treat certain forms of leukemia and other cancers.